Autacoids and related drugs market seen reaching $70.07 billion by 2030

By AI, Created 10:15 AM UTC, May 20, 2026, /AGP/ – The global autacoids and related drugs market is projected to grow from $55.87 billion in 2026 to $70.07 billion by 2030, driven by rising cardiovascular, inflammatory and allergic disease burdens. North America led the market in 2025, while Asia-Pacific is expected to grow the fastest through the forecast period.

Why it matters: - The autacoids and related drugs market is expanding as chronic disease treatment needs rise worldwide. - The category plays a role in treating cardiovascular, inflammatory, allergic and gastrointestinal conditions, making it relevant across several major care areas. - Growth in this segment could shape demand for receptor-targeted therapies and combination treatment approaches through 2030.

What happened: - The Business Research Company released its Autacoids and Related Drugs Global Market Report 2026 covering market size, trends and forecasts through 2035. - The report estimates the market will rise from $52.81 billion in 2025 to $55.87 billion in 2026. - The report projects the market will reach $70.07 billion by 2030. - The report puts the market on a 5.8% CAGR path for both the 2025-2026 period and the 2026-2030 forecast window. - North America led the global market in 2025. - Asia-Pacific is expected to post the fastest growth rate over the forecast period.

The details: - Market growth has been supported by rising prevalence of inflammatory diseases, growing allergy cases, cardiovascular disease burden, greater need for gastrointestinal disorder treatments and broader hospital pharmacology use. - Future growth is expected to come from precision pharmacology, receptor-targeted therapies, chronic disease management, outpatient treatment expansion and combination therapies. - Emerging trends in the report include broader use in inflammatory disease control, more receptor-specific drug action, rising demand for targeted autacoid modulators, and expanded use in cardiovascular and respiratory care. - Autacoids are naturally occurring biologically active substances produced in the body that regulate local physiological functions in specific tissues or organs. - Autacoids influence inflammation, smooth muscle contraction, immune responses and blood flow regulation. - Autacoids work by binding to specific receptors on target cells and activating signaling pathways that change cellular activity. - Cardiovascular disease remains a major growth driver for the market because autacoids and related drugs help regulate vascular tone and reduce inflammation. - Pathways involving nitric oxide, endothelin and prostacyclin are used to restore endothelial function, support vasodilation and lower vascular resistance. - The World Health Organization said cardiovascular diseases caused 17.9 million deaths worldwide in September 2023. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The market outlook suggests autacoids are moving further into targeted, mechanism-based treatment as drug development becomes more precise. - The combination of rising chronic disease burden and outpatient care growth points to broader use beyond traditional hospital settings. - North America’s current lead and Asia-Pacific’s faster growth signal a market that is both mature in some regions and expanding quickly in others.

What’s next: - The report points to continued demand growth through 2030 as chronic disease management and targeted therapies expand. - Innovation in receptor-specific drugs and combination regimens is likely to remain a key watchpoint for the sector. - Download the free sample or view the full report.